Department of Infectious Diseases Huddinge, I73, Karolinska University Hospital, 141 86, Stockholm, Sweden.
Department of Obstetrics and Gynecology, Karolinska University Hospital, 141 86, Stockholm, Sweden.
Infection. 2023 Feb;51(1):261-263. doi: 10.1007/s15010-022-01829-4. Epub 2022 Apr 28.
Pregnancy is a risk factor for severe COVID-19. Treatment with monoclonal antibodies has been shown to decrease the risk of progression to severe COVID-19, but there are few reports on treating pregnant women. Here, we describe the clinical outcome of seven hospitalized pregnant women treated with the casirivimab-imdevimab.
METHODS/RESULTS: Seven unvaccinated pregnant patients hospitalized due to COVID-19 met the monoclonal antibodies treatment criteria applied at our center. After consultations with obstetricians, the decisions to administer casirivimab-imdevimab to halt the progression of COVID-19 were made by two senior infectious diseases specialists. No patient experienced an adverse drug reaction, and only one patient progressed to severe disease. Two patients had a cesarian section performed during hospitalization, both with delivery of healthy babies. Three patients gave birth to healthy babies at a later time point, while two pregnancies are ongoing.
The hospitalized pregnant patients who received monoclonal antibodies due to COVID-19 had favorable outcomes, but further research is recommended to fully assess safety and efficacy of monoclonal antibody treatment in pregnancy.
妊娠是发生严重 COVID-19 的危险因素。已有研究表明，使用单克隆抗体治疗可降低发展为严重 COVID-19 的风险，但关于治疗孕妇的报道较少。在此，我们描述了 7 例接受 casirivimab-imdevimab 治疗的住院孕妇的临床结局。
方法/结果：7 例未接种疫苗的因 COVID-19 住院的孕妇符合我们中心应用的单克隆抗体治疗标准。与产科医生协商后，由两名资深传染病专家决定使用 casirivimab-imdevimab 来阻止 COVID-19 的进展。没有患者出现药物不良反应，仅有 1 例进展为重症。2 例患者在住院期间行剖宫产术，均分娩出健康婴儿。另外 3 例患者在后续时间点分娩出健康婴儿，还有 2 例妊娠仍在继续。
因 COVID-19 接受单克隆抗体治疗的住院孕妇结局良好，但需要进一步研究以充分评估单克隆抗体治疗在妊娠中的安全性和有效性。
Zotero 插件